Inhibikase Therapeutics, INC Schedule 13G passive stakes

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 4.30% in InhibiKinase Therapeutics, Inc. as of June 30, 2026.

Sands Capital entities report a combined 9.3% ownership in Inhibikase Therapeutics, Inc., holding over 13 million shares.

RA Capital Management, along with affiliated entities and individuals, has reported beneficial ownership of 9.9% of Inhibikase Therapeutics' common stock.

RA Capital Management and affiliated entities have jointly filed a Schedule 13G, reporting beneficial ownership of 15.9% of Inhibikase Therapeutics' common stock.

ADAR1 Capital Management and Daniel Schneeberger have reported a 9.9% beneficial ownership stake in Inhibikase Therapeutics, Inc.

Trails Edge Capital Partners and Ortav Yehudai have reported a 6.1% beneficial ownership stake in Inhibikase Therapeutics, Inc.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 5.68% beneficial ownership stake in Inhibikase Therapeutics, Inc.

Sands Capital Life Sciences Pulse Fund II, L.P. and affiliates report a 10.8% beneficial ownership stake in Inhibikase Therapeutics, Inc.

Trails Edge Capital Partners and affiliated entities report a 5.1% passive beneficial ownership in Inhibikase Therapeutics, Inc.

ADAR1 Capital Management, its general partner, and Daniel Schneeberger have disclosed a 9.9% beneficial ownership stake in Inhibikase Therapeutics, Inc. as of June 30, 2025.

Sands Capital entities report a 14.7% beneficial ownership stake in Inhibikase Therapeutics, Inc., holding over 10.9 million shares.

ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger have jointly filed a Schedule 13G, disclosing beneficial ownership of 9.99% of Inhibikase Therapeutics, Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% in Inhibikase Therapeutics, Inc. as of December 31, 2024.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 7.54% in Inhibikase Therapeutics, Inc. as of December 31, 2024.

Point72 Asset Management, along with its affiliates Point72 Capital Advisors Inc. and Steven A. Cohen, has filed an amendment to their Schedule 13G, indicating they no longer hold a reportable beneficial ownership stake in Inhibikase Therapeutics, Inc. as of December 31, 2024.

Fairmount Funds Management LLC and its affiliates have disclosed a 9.9% beneficial ownership stake in Inhibikase Therapeutics, Inc., comprising common stock and exercisable pre-funded warrants, as of December 31, 2024.